← Leaderboards
Gary P. Wang
University Of Pennsylvania
$4,044,506
Attributed
$4,160,722
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2009–24$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,160,722 · 7
VA$0 · 1
By mechanism
R42$1,999,999 · 1
R21$818,813 · 2
K08$526,608 · 1
R56$329,625 · 1
R41$253,244 · 1
R43$232,433 · 1
Top collaborators
- Richard Wagner1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Benjamin S Schuster$2,173,757
- Falk W Lohoff$948,970
- Robert J Derubeis$8,551,105
- Arjun Raj$12,538,737
- Jennifer Elizabeth Phillips-Cremins$16,516,249
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistanceSamplingBaseInnovationFutureNovel StrategiesLeadEvolutionMicrobialStructureSuccessLaboratoriesIndigenousGut MicrobiotaGenesMonitorDrug ResistanceInsightMicrobiomePreventMicrobeMicrobiotaCessation Of LifeFecal Transplantation
Grant awards (21)
Defining omic-signatures in recurrent Clostridium difficile infection$0
I01 · FY2024 · VA · contact PI
A method for accurate and sensitive detection of HIV drug-resistant minority variants$1,000,000
R42 · FY2023 · AI · contact PI
Defining omic-signatures in recurrent Clostridium difficile infection$0
I01 · FY2023 · VA · contact PI
A method for accurate and sensitive detection of HIV drug-resistant minority variants$999,999
R42 · FY2022 · AI · contact PI
Defining omic-signatures in recurrent Clostridium difficile infection$0
I01 · FY2022 · VA · contact PI
Cultivable commensal spores in C. difficile infection$183,783
R21 · FY2021 · AI · contact PI
Defining omic-signatures in recurrent Clostridium difficile infection$0
I01 · FY2021 · VA · contact PI
Cultivable commensal spores in C. difficile infection$222,530
R21 · FY2020 · AI · contact PI
Defining omic-signatures in recurrent Clostridium difficile infection$0
I01 · FY2020 · VA · contact PI
Defining omic-signatures in recurrent Clostridium difficile infection$0
I01 · FY2019 · VA · contact PI
Next generation quantitative HCV drug resistance assay$232,433
R43 · FY2017 · DK
Defining omic-signatures in recurrent Clostridium difficile infection$0
I01 · FY2017 · VA · contact PI
A method for accurate and sensitive detection of HIV drug-resistant minority variants$253,244
R41 · FY2016 · AI · contact PI
Regulation of tryptophan metabolism and anxiety by gut microbiota$225,000
R21 · FY2016 · MH · contact PI
Regulation of tryptophan metabolism and anxiety by gut microbiota$187,500
R21 · FY2015 · MH · contact PI
HCV diversity and resistance analyzed by DNA bar coding and pyrosequencing$131,652
K08 · FY2012 · AI · contact PI
HCV diversity and resistance analyzed by DNA bar coding and pyrosequencing$131,652
K08 · FY2011 · AI · contact PI
Human Oral Microbiome in Periodontal Disease and HIV Infection$329,625
R56 · FY2010 · DE · contact PI
HCV diversity and resistance analyzed by DNA bar coding and pyrosequencing$131,652
K08 · FY2010 · AI · contact PI
HCV diversity and resistance analyzed by DNA bar coding and pyrosequencing$110,240
K08 · FY2009 · AI · contact PI
HCV diversity and resistance analyzed by DNA bar coding and pyrosequencing$21,412
K08 · FY2009 · AI · contact PI